ArticleFrontiers in oncology2026
Tumor Treating Fields (TTFields), and their concomitant application with FOLFOX, are effective for the treatment of gastric cancer cells.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields).Cell death discovery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor Treating Fields (TTFields) are electric fields that exert antimitotic effects and impair DNA damage repair in cancerous cells. Gastric cancer, one of the most common types of cancers worldwide, demonstrates poor long-term survival despite advances in therapeutic options. The goal of the current study was to examine Methods: Human gastric cancer cell lines, AGS and KATOIII, were treated with TTFields using the inovitro system. To test the efficacy of TTFields (alone or together with oxaliplatin, 5-FU, or FOLFOX), cell count, colony formation, and apoptosis were examined. For mechanistic insight, control and TTFields-treated cells were examined by RNA sequencing. Immunofluorescent staining for phospho-histone H2AX (γH2AX), α-tubulin, phospho-histone 3 (pH3), and double stranded DNA was employed for detection of DNA damage, mitotic spindle defects, chromosome mislocalization, and micronuclei clusters, respectively. Expression of DNA damage repair proteins was measured using Western Blot. Results: Maximal cell count reduction following application of TTFields at various frequencies was identified at 150 kHz. Treatment also led to reduced colony formation, elevated apoptosis, and substantial changes in transcriptomic expression. TTFields-treated cells demonstrated increased DNA damage, elevated expression of DNA damage-related cyclin-dependent kinase (CDK) inhibitors, and reduced expression of proteins from the Fanconi Anemia-BRCA pathway for DNA repair. Treated cells further presented with abnormal mitotic figures, chromosome mislocalization, and micronuclei clusters, indicative of an antimitotic effect of TTFields. The application of TTFields concomitant with oxaliplatin, 5-FU or FOLFOX was more effective than each treatment alone. Conclusions: The study shows that TTFields induce an antimitotic effect and impair DNA damage repair in gastric cancer cells, and that concomitant treatment with FOLFOX improves treatment efficacy
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.